GH Research GHRS
NASDAQ GHRS
$28.01 +0.09 (+0.32%)
As of: Sep 4, 2026 · 2:31 PM EDT

GH Research (GHRS) Profit After Tax (2020 - 2026)

GH Research (GHRS) posted quarterly Profit After Tax of -$14.1 million for Q4 2025, down 60.61% year-over-year from -$35.9 million in Q4 2024, and down 0.83% quarter-over-quarter from -$14.0 million in Q3 2025.

Analysis

GH Research (GHRS) Profit After Tax (2020 - 2026) Analysis & Trends

GH Research's Profit After Tax history runs 6 years deep, the most recent figure standing at -$14.1 million for Q4 2025.

  • In Q4 2025, Profit After Tax fell 60.61% year-over-year to -$14.1 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 23.86% YoY), while the FY2025 annual figure was -$48.3 million, down 23.86% from the prior year.
  • Profit After Tax for Q4 2025 stood at -$14.1 million, down from -$14.0 million in the prior quarter.
  • The five-year high for Profit After Tax was $334000.0 in Q2 2022, with the low at -$16.6 million in Q4 2022.
  • The 5-year median for Profit After Tax is -$8.4 million (2022), against an average of -$7.8 million.
  • The sharpest annual moves came in 2021 and 2022: Profit After Tax tumbled 19066.67% in 2021, then jumped 168.72% in 2022.
  • GH Research's Profit After Tax stood at -$5.7 million in 2021, then tumbled by 192.57% to -$16.6 million in 2022, then jumped by 32.04% to -$11.3 million in 2023, then advanced by 21.91% to -$8.8 million in 2024, then plunged by 60.61% to -$14.1 million in 2025.
  • Business Quant data shows GHRS's Profit After Tax at -$14.1 million in Q4 2025, -$14.0 million in Q3 2025, and -$9.3 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -644.37 Mn
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.40 Bn 27.56 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -16.62 Mn
10 GH Research 1.71 Bn 1.35 Bn - -17.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -17.75 Mn
Mar 31, 2026 -18.23 Mn
Dec 31, 2025 -14.35 Mn
Sep 30, 2025 -14.12 Mn
Jun 30, 2025 -8.91 Mn
Mar 31, 2025 -10.22 Mn
Dec 31, 2024 -11.17 Mn
Sep 30, 2024 -9.58 Mn
Jun 30, 2024 -10.93 Mn
Mar 31, 2024 -9.50 Mn
Dec 31, 2023 58.85 Mn
Sep 30, 2023 -7.86 Mn
Jun 30, 2023 -9.30 Mn
Mar 31, 2023 -8.54 Mn
Dec 31, 2022 -807,000.00
Sep 30, 2022 -6.91 Mn
Jun 30, 2022 -6.72 Mn
Mar 31, 2022 -8.02 Mn
Dec 31, 2021 18.84 Mn
Sep 30, 2021 -2.85 Mn